Hypha Labs (FUNI) 10-K 29 Dec 21 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Sep. 30, 2021	Dec. 27, 2021	Mar. 31, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--09-30
Entity File Number	000-54239
Entity Registrant Name	DIGIPATH, INC.
Entity Central Index Key	0001502966
Entity Tax Identification Number	27-3601979
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	6450 Cameron Street
Entity Address, Address Line Two	Suite 113
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	(702)
Local Phone Number	527-2060
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 3,201,921
Entity Common Stock, Shares Outstanding		72,730,153

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Current assets:
Cash	$ 295,932	$ 82,749
Accounts receivable, net	214,900	242,145
Deposits	24,751	18,675
Note receivable	230,929
Other current assets	60,353	53,673
Total current assets	826,865	397,242
Right-of-use asset	413,884	505,706
Fixed assets, net	647,252	885,405
Total non-current assets	1,061,136	1,391,111
Total Assets	1,888,001	1,788,353
Current liabilities:
Accounts payable	370,977	387,946
Accrued expenses	220,002	163,152
Short term advances		50,112
Current portion of operating lease liabilities	93,601	84,731
Current portion of finance lease liabilities	20,379	32,532
Current maturities of notes payable	259,425	54,317
Current maturities of convertible notes payable	1,050,000
Total current liabilities	2,014,384	772,790
Non-current liabilities:
Operating lease liabilities	330,151	423,752
Finance lease liabilities		20,379
Notes payable	339,516	418,907
Convertible notes payable, net of discounts of $98,188 and $8,322 at September 30, 2021 and 2020, respectively	257,282	1,241,678
Total non-current liabilities	926,949	2,104,716
Total Liabilities	2,941,333	2,877,506
Stockholders’ Equity (Deficit):
Series A convertible preferred stock, $0.001 par value, 10,000,000 shares authorized; 1,325,942 shares issued and outstanding	1,326	1,326
Common stock, $0.001 par value, 250,000,000 shares authorized; 71,230,153 and 58,270,567 shares issued and outstanding at September 30, 2021 and 2020, respectively	71,230	58,271
Additional paid-in capital	16,825,765	16,116,400
Accumulated deficit	(17,951,653)	(17,265,150)
Total Stockholders’ Equity (Deficit)	(1,053,332)	(1,089,153)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 1,888,001	$ 1,788,353

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Statement of Financial Position [Abstract]
Debt instrument, unamortized discount, noncurrent	$ 98,188	$ 8,322
Series A convertible preferred stock, par value	$ 0.001	$ 0.001
Series A convertible preferred stock, shares authorized	10,000,000	10,000,000
Series A convertible preferred stock, shares issued	1,325,942	1,325,942
Series A convertible preferred stock, shares outstanding	1,325,942	1,325,942
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	71,230,153	58,270,567
Common stock, shares outstanding	71,230,153	58,270,567

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenues	$ 2,503,800	$ 2,574,399
Cost of sales	1,788,635	1,778,564
Gross profit	715,165	795,835
Operating expenses:
General and administrative	934,143	1,483,253
Professional fees	581,635	782,885
Bad debts expense (recovery)	(28,165)	91,558
Impairment expense		630,521
Total operating expenses	1,487,613	2,988,217
Operating loss	(772,448)	(2,192,382)
Other income (expense):
Interest expense	(144,957)	(148,024)
Interest Income	929
Gain on settlement of debt	222,393
Other Income	7,580	81,009
Loss on disposal of fixed assets		(50,093)
Total other income (expense)	85,945	(117,108)
Net Loss	$ (686,503)	$ (2,309,490)
Net loss per share - basic and fully diluted	$ (0.01)	$ (0.04)
Weighted average number of common shares outstanding - basic and fully diluted	65,868,108	53,455,848

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Sep. 30, 2019	$ 1,326	$ 48,361	$ 15,331,839	$ (14,955,660)	$ 425,866
Beginning balance, shares at Sep. 30, 2019	1,325,942	48,361,433
Common stock sold for cash		$ 706	55,794		56,500
Common stock sold for cash, shares		706,250
Common stock issued for acquisition of VSSL Enterprises, Ltd.		$ 6,500	367,250		373,750
Common stock issued for acquisition of VSSL Enterprises, Ltd., shares		6,500,000
Common stock issued for services		$ 2,704	149,846		152,550
Common stock issued for services, shares		2,702,884
Common stock options issued for services			141,659		141,659
Common stock warrants issued for services			70,012		70,012
Net loss				(2,309,490)	(2,309,490)
Ending balance, value at Sep. 30, 2020	$ 1,326	$ 58,271	16,116,400	(17,265,150)	(1,089,153)
Ending balance, shares at Sep. 30, 2020	1,325,942	58,270,567
Common stock sold for cash		$ 900	19,350		20,250
Common stock sold for cash, shares		900,000
Common stock issued for debt conversion		$ 6,666	193,334		200,000
Common stock issued for debt conversion, shares		6,666,668
Common stock issued for services		$ 5,393	250,862		256,255
Common stock issued for services, shares		5,392,918
Common stock options issued for services			147,631		147,631
Beneficial conversion feature on convertible notes payable			98,188		98,188
Net loss				(686,503)	(686,503)
Ending balance, value at Sep. 30, 2021	$ 1,326	$ 71,230	$ 16,825,765	$ (17,951,653)	$ (1,053,332)
Ending balance, shares at Sep. 30, 2021	1,325,942	71,230,153

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (686,503)	$ (2,309,490)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in allowance for doubtful accounts	(28,165)	91,558
Depreciation and amortization expense	292,133	323,391
Gain on settlement of debt	(222,393)
Loss on disposal of fixed assets		50,093
Gain on modification of operating leases		(1,724)
Inventory impairment		37,900
Goodwill impairment		592,621
Stock issued for services	256,255	152,550
Options and warrants granted for services	147,631	211,671
Amortization of debt discounts	8,322	33,104
Decrease (increase) in assets:
Accounts receivable	55,410	(152,862)
Other current assets	(7,609)	26,206
Inventory		(37,900)
Deposits	(6,076)	33,029
Right-of-use assets	91,822	182,120
Increase (decrease) in liabilities:
Accounts payable	(14,743)	248,754
Accrued expenses	62,679	24,993
Lease liabilities	(84,731)	(177,619)
Net cash (used) in operating activities	(135,968)	(671,605)
Cash flows from investing activities
Cash acquired from affiliate in acquisition of VSSL		143
Cash paid for purchase of VSSL Enterprises, Ltd.		(200,000)
Purchase of fixed assets	(56,206)	(141,151)
Advance of note receivable	(230,000)
Net cash (used) in investing activities	(286,206)	(341,008)
Cash flows from financing activities
Proceeds from short term advances	65,000	55,112
Repayments of short term advances	(30,112)	(25,000)
Principal payments on finance lease	(32,532)	(46,282)
Principal payments on note payable, equipment financing	(54,249)	(38,741)
Proceeds from notes payable	400,000	220,034
Proceeds from convertible notes	267,000	550,000
Proceeds from sale of common stock	20,250	56,500
Net cash provided by financing activities	635,357	771,623
Net increase (decrease) in cash	213,183	(240,990)
Cash - beginning	82,749	323,739
Cash - ending	295,932	82,749
Supplemental disclosures:
Interest paid	45,357	57,906
Income taxes paid
Non-cash investing and financing activities:
Fair value of net assets acquired in business combination from affiliate		18,871
Fair value of common stock paid in business combination from affiliate		373,750
Fixed assets acquired with capitalized finance lease		99,193
Fixed assets acquired with note payable, equipment financing		291,931
Fixed assets transferred to settle accounts payable	2,226
Common stock issued for debt conversion	200,000
Transfer of notes payable and accrued interest into convertible notes payable	88,470
Beneficial conversion feature on convertible notes payable	$ 98,188

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	Note 1 – Nature of Business and Significant Accounting Policies Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory and data analytics company focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015 and has plans to open labs in other states and countries that have legalized the sale of cannabis, beginning with California. Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles. The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2021: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity (1) Incorporation Relationship Digipath, Inc (2) (2) Nevada Parent Digipath Labs, Inc Nevada Subsidiary TNM News, Inc (6) (6) Nevada Subsidiary GroSciences, Inc (3) (3) Colorado Subsidiary Digipath Labs S.A.S (4) (4) Colombia Subsidiary VSSL Enterprises, Ltd (5) (5) Canada Subsidiary Digipath Labs CA, Inc (7) (7) Nevada Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Commenced operations during the first fiscal quarter of 2019, and had minimal operations until being dissolved on September 30, 2020. (4) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (5) Acquired on March 11, 2020. (6) Dissolved on July 28, 2021, trivial operating expenses during fiscal years September 30 2021 and 2020. (7) Formed during the fourth fiscal quarter of 2021, but has not yet commenced significant operations. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations. Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $ 96,285 128,944 The Company had one customer representing 27% 10% 29% 25% 10% 24% Notes Receivable Notes receivable are reported in our consolidated balance sheets at the outstanding principal balance, plus costs incurred to originate the loans, net of any unamortized premiums or discounts on purchased loans. We use the effective interest rate method to recognize finance income, which produces a constant periodic rate of return on the investment. Unearned income, discounts and premiums are amortized to finance income in our consolidated statements of operations using the effective interest rate method. Interest receivable related to the unpaid principal is recorded together with the outstanding balance in our consolidated balance sheets. Upon the prepayment of a note receivable, any prepayment penalties and unamortized loan origination, closing and commitment fees are recorded as part of finance income in our consolidated statements of operations. Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations. Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. Our intellectual property is comprised of indefinite-lived brand names acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables. Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $ 28,050 45,120 Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2021 and 2020, potential dilutive securities had an anti-dilutive effect and were no Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	12 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying consolidated financial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of $ 17,951,653 The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Acquisition from Affiliate

Acquisition from Affiliate	12 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisition from Affiliate	Note 3 – Acquisition from Affiliate On March 9, 2020, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with VSSL Enterprises Ltd (“VSSL”), Kyle Joseph Remenda (“Remenda”), Philippe Olivier Henry, PhD (“Henry”), Audim Ventures Ltd. (“Audim”), and Britt Ash Enterprises Ltd. (“Britt Ash” and, together with Remenda, Henry and Audim, the “VSSL Stockholders”), pursuant to which the Company acquired all of VSSL’s outstanding shares of capital stock from the VSSL Stockholders for consideration consisting of 6,500,000 200,000 March 11, 2020 373,750 Mr. Remenda, who held 45 45 This acquisition was accounted for as a business combination under the purchase method of accounting. The purchase resulted in the recognition of $ 592,621 Schedule of Recognized Identifiable Assets Acquired and Liabilities Assumed March 11, 2020 Consideration: Cash $ 200,000 Fair value of 6,500,000 373,750 Liabilities assumed 20,600 Total consideration $ 594,350 Fair value of identifiable assets acquired assumed: Cash $ 143 Accounts receivable 1,586 Total fair value of assets assumed 1,729 Consideration paid in excess of fair value (Impaired Goodwill) (1) $ 592,621 (1) The consideration paid in excess of the net fair value of assets acquired and liabilities assumed was recognized as goodwill and determined to be impaired on September 30, 2020 due to the lack of significant revenues, and our inability to fund the necessary research and development to develop its assets. Pro Forma Results The following table sets forth the unaudited pro forma results of the Company as if the acquisition of VSSL was effective on the first day of each of the periods presented. These combined results are not necessarily indicative of the results that may have been achieved had the companies always been combined. Schedule of Business Acquisition Pro Forma Information For the year ended September 30, 2020 (Unaudited) Revenues $ 2,588,803 Net loss $ (2,343,662 ) Basic and diluted net loss per share $ ( 0.04 ) Weighted average number of common shares outstanding - basic and fully diluted 56,350,657

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Sep. 30, 2021
Investments, All Other Investments [Abstract]
Fair Value of Financial Instruments	Note 4 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2021 and 2020, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Fair Value Measurements at September 30, 2021 Level 1 Level 2 Level 3 Assets Cash $ 295,957 $ - $ - Liabilities Lease liabilities - - 444,131 Notes payable - 598,941 - Convertible notes payable, net of discounts of $ 98,188 - - 1,307,282 Fair Value Measurements at September 30, 2020 Level 1 Level 2 Level 3 Assets Cash $ 82,749 $ - $ - Liabilities Short term advances - 50,112 - Lease liabilities - - 561,394 Notes payable - 473,224 - Convertible notes payable, net of discounts of $ 8,322 - - 1,241,678 Convertible notes payable, net of discounts of $98,188 and $8,322 - - 1,241,678 The fair value of our intellectual properties is deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the years ended September 30, 2021 or 2020.

Note Receivable

Note Receivable	12 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
Note Receivable	Note 5 – Note Receivable On various dates between December 28, 2018 and June 13, 2019, we loaned Northwest Analytical Labs, Inc. a total of $ 95,000 10 On various dates between August 23, 2021 and September 20, 2021, we loaned C3 Labs, Inc. a total of $ 230,000 . The loans bear interest at an annual rate of 8 %, are evidenced by secured demand notes, are secured by a lien on the borrower’s assets, and have a maturity date of August 23, 2022 929 during the year ended September 30, 2021 with total accrued interest of $ 929 as of September 30, 2021.

Fixed Assets

Fixed Assets	12 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 6 – Fixed Assets Fixed assets consist of the following at September 30, 2021 and 2020: Schedule of Fixed Assets 2021 2020 As of September 30, 2021 2020 Software $ 125,903 $ 124,697 Office equipment 71,601 74,777 Furniture and fixtures 29,879 29,879 Lab equipment 1,453,716 1,398,716 Leasehold improvements 494,117 494,117 Lab equipment held under capital leases 99,193 99,193 Fixed assets, gross 2,274,409 2,221,379 Less: accumulated depreciation (1,627,157 ) (1,335,974 ) Total $ 647,252 $ 885,405 On various dates from June 30, 2020 through September 30, 2020, the Company disposed of lab equipment no longer in service. No proceeds were received on the disposal of the equipment, resulting in a loss on disposal of fixed assets of $ 50,093 On March 31, 2021, we distributed fixed assets with an aggregate net book value of $ 2,227 3,176 949 2,227 Depreciation and amortization expense totaled $ 292,133 323,391

Leases

Leases	12 Months Ended
	Sep. 30, 2021
Leases
Leases	Note 7 – Leases The Company leases its operating and office facility under a non-cancelable real property lease agreement that expires on August 31, 2025 The components of lease expense were as follows: Schedule of Components of Lease Expense For the For the Year Ended Year Ended September 30, 2021 September 30, 2020 Operating lease cost $ 118,873 $ 207,772 Finance lease cost: Amortization of assets 19,839 20,224 Interest on lease liabilities 7,310 10,696 Sublease income - (79,285 ) Total net lease cost $ 146,022 $ 159,407 Supplemental balance sheet information related to leases was as follows: Schedule of Supplemental Balance Sheet Information September 30, 2021 September 30, 2021 Operating leases: Operating lease assets $ 413,884 $ 505,706 Current portion of operating lease liabilities 93,601 $ 84,731 Noncurrent operating lease liabilities 330,151 423,752 Total operating lease liabilities $ 423,752 $ 508,483 Finance lease: Equipment, at cost $ 99,193 $ 99,193 Accumulated amortization (39,677 ) (19,839 ) Equipment, net $ 59,516 $ 79,354 Current portion of finance lease liabilities $ 20,379 $ 32,532 Noncurrent finance lease liabilities - 20,379 Total finance lease liabilities $ 20,379 $ 52,911 Weighted average remaining lease term: Operating leases 3.92 4.92 Finance leases 0.55 1.55 Weighted average discount rate: Operating leases 5.75 % 5.75 % Finance lease 18.41 % 18.41 % Supplemental cash flow and other information related to leases was as follows: Schedule of Supplemental Cash Flow and Other Information For the For the Year Ended Year Ended September 30, 2021 September 30, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows provided by sublet operating leases $ - $ 79,285 Operating cash flows used for operating leases $ 84,731 $ 177,619 Financing cash flows used for finance leases $ 32,532 $ 46,282 Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ - $ 528,616 Total finance lease liabilities $ - $ 99,193 The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of September 30, 2021: Schedule of Future Minimum Annual Lease Commitments Under Operating Leases Fiscal Year Ending Minimum Lease September 30, Commitments 2022 $ 115,550 2023 119,468 2024 123,543 2025 116,891 2026 - Total future undiscounted lease payments 475,452 Less interest 51,701 Present value of lease payments 423,752 Less current portion 93,601 Long-term operating lease liabilities $ 330,151 Future minimum annual lease payments required under the finance lease and the present value of the net minimum lease payments are as follows at September 30, 2021: Schedule of Future Minimum Annual Lease Payments Under Finance Lease Finance Leases 2022 $ 21,645 2023 - Total minimum lease payments 21,645 Less interest 1,266 Present value of lease liabilities 20,379 Less current portion 20,379 Long-term finance lease liabilities $ -

Short Term Advances

Short Term Advances	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Short Term Advances	Note 8 – Short Term Advances Short term advances consist of the following at September 30, 2021 and 2020, respectively: Schedule of Short Term Advances September 30, 2021 September 30, 2020 On July 20, 2020, we received $ 30,112 8.0 $ $ 30,112 On January 21, 2020, we received $ 20,000 - 20,000 Total short term advances $ - $ 50,112 The Company recorded interest expense pursuant to the stated interest rates on the short term loans in the amount of $ 2,356

Notes Payable

Notes Payable	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Notes Payable	Note 9 – Notes Payable Notes payable consists of the following at September 30, 2021 and 2020, respectively: Schedule of Notes Payable September 30, 2021 September 30, 2020 On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 6,750,000 12 September 10, 2024 22,419.66 400,000 $ 400,000 $ - On March 23, 2021; April 29, 2021; July 12, 2021; July 22, 2021 and August 23, 2021, we received proceeds of $ 40,000 25,000 7,000 100,000 50,000 8 $ - $ - On June 22, 2020, the Company, borrowed $ 40,114 1.00 June 22, 2025 40,338 $ - $ 40,114 On May 13, 2020, the Company, through its wholly-owned subsidiary Digipath Labs, Inc. (“Labs”), borrowed $ 179,920 1.00 May 13, 2022 182,054 - 179,920 On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five December 26, 2024 198,941 253,190 Total notes payable 598,941 473,224 Less: current maturities (259,425 ) (54,317 ) Notes payable $ 339,516 $ 418,907 The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 14,700

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 10 – Convertible Notes Payable Convertible notes payable consist of the following at September 30, 2021 and 2020, respectively: Schedule of Convertible Notes Payable September 30, 2021 September 30, 2020 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 150,000 150,000 On February 10, 2020, the Company completed the sale to an accredited investor of a 9 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 350,000 350,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 On September 30, 2020, the maturity date was extended to August 10, 2022 0.03 90,000 3,000,000 0.03 355,470 December 31, 2022 98,188 355,470 200,000 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 the maturity date was extended to August 10, 2022 0.03 350,000 350,000 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 the maturity date was extended to August 10, 2022 0.03 150,000 150,000 Total convertible notes payable 1,405,470 1,250,000 Less: unamortized debt discounts (98,188 ) (8,322 ) Total convertible debt 1,307,282 1,241,678 Less: current maturities 1,050,000 - Convertible notes payable $ 257,282 $ 1,241,678 In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt. The aforementioned accounting treatment resulted in a total debt discount equal to $ 98,188 70,964 8,322 33,104 98,188 All of the convertible notes limit the maximum number of shares that can be owned by each note holder as a result of the conversions to common stock to 4.99 The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $ 102,901 87,690 The Company recognized interest expense for the years ended September 30, 2021 and 2020, respectively, as follows: Schedule of Interest Expense September 30, 2021 September 30, 2020 Interest on short term loans $ 1,558 $ 61 Interest on capital leases 20,874 10,696 Interest on notes payable 11,302 16,473 Amortization of beneficial conversion features 8,322 33,104 Interest on convertible notes 102,901 87,690 Total interest expense $ 144,957 $ 148,024

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders’ Equity	Note 11 – Stockholders’ Equity Convertible Preferred Stock The Company is authorized to issue 10,000,000 0.001 6,000,000 4,000,000 1,325,942 The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,325,942 6,629,710 4.99 Additional terms of the Series A Preferred include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99 ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100 ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99 ● Consent of the holders of the outstanding Series A Preferred is required in order for the Company to: (i) amend or change the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, the Series A Preferred; (ii) authorize, create or issue shares of any class of stock having rights, preferences, privileges or powers superior to the Series A Preferred; (iii) reclassify any outstanding shares into shares having rights, preferences, privileges or powers superior to the Series A Preferred; or (iv) amend the Company’s Articles of Incorporation or Bylaws in a manner that adversely affects the rights of the Series A Preferred. ● Pursuant to the Securities Purchase Agreements, holders of Series A Preferred are entitled to unlimited “piggyback” registration rights on registrations by the Company, subject to pro rata cutback at any underwriter’s discretion. Common Stock Common stock consists of $ 0.001 250,000,000 71,230,153 Common Stock Transactions for the Year Ended September 30, 2021 On December 30, 2020, the Company sold 900,000 20,250 During the year ending September 30, 2021 the Company issued 5,392,918 256,255 2,744,585 1,898,333 750,000 During the year ending September 30, 2021 the Company issued 6,666,668 200,000 Common Stock Transactions for the Year Ended September 30, 2020 During the year ending September 30, 2020, the Company sold 706,250 56,500 On March 11, 2020, the Company acquired all of VSSL’s outstanding shares of capital stock from VSSL’s stockholders for consideration consisting of 6,500,000 200,000 373,750 During the year ending September 30, 2020 the Company issued 2,702,884 152,550 1,452,884 1,250,000 Amortization of Stock-Based Compensation A total of $ 256,255 5,392,918 A total of $ 152,550 2,702,884

Common Stock Options

Common Stock Options	12 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Common Stock Options	Note 12 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012 and previously amended on May 20, 2014. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 6,370,000 Common Stock Option Issuances During the year ending September 30, 2021 the Company issued options to purchase 2,800,000 142,862 2 167 185 0.0463 0.0576 0.0481 0.06 1,000,000 1,800,000 During the year ending September 30, 2020 the Company issued options to purchase 3,700,000 166,953 2 110 238 0.0403 0.0683 0.10 1,500,000 2,000,000 200,000 Amortization of Stock-Based Compensation A total of $ 147,630 141,659 60,628 The following is a summary of information about the stock options outstanding at September 30, 2021. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.05 0.13 5,620,000 7.41 $ 0.08 4,370,000 $ 0.08 The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Weighted-Average Assumptions Used for Grants Under Fixed Option Plan September 30, September 30, 2021 2020 Average risk-free interest rates 0.88 % 0.92 % Average expected life (in years) 5.00 5.00 Volatility 156 % 141 % The Black-Scholes option pricing model was developed for use in estimating the fair value of short-term traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including expected stock price volatility. Because the Company’s common stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models do not necessarily provide a reliable single measure of the fair value of its common stock options. During the years ended September 30, 2021 and September 30, 2020, there were no The weighted average fair value of options granted with exercise prices at the current fair value of the underlying stock during the year ended September 30, 2021 was approximately $ 0.05 The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2019 6,085,000 0.13 Options issued 3,700,000 0.10 Options repurchased/expired (6,215,000 ) (0.13 ) Balance, September 30, 2020 3,570,000 $ 0.11 Options issued 2,800,000 0.05 Options forfeited (750,000 ) (0.10 ) Balance, September 30, 2021 5,620,000 $ 0.08 Exercisable, September 30, 2021 4,370,000 $ 0.08 As of September 30, 2021, these options in the aggregate had no intrinsic value as the per share market price of $ 0.042 0.08

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Sep. 30, 2021
Common Stock Warrants
Common Stock Warrants	Note 13 – Common Stock Warrants Warrants to purchase a total of 2,535,001 On March 9, 2020, we granted a ten-year warrant to purchase 1,500,000 0.10 110 0.0467 70,012 On February 21, 2020, warrants to purchase 642,857 0.26 During the year ended September 30, 2021, warrants to purchase an aggregate total of 1,739,268 0.25 The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2021 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.10 0.26 2,535,001 5.34 $ 0.17 2,535,001 $ 0.17 The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Fair Value of Warrant with Weighted-Average Assumptions Used for Grants September 30, September 30, 2021 2020 Average risk-free interest rates - % 0.46 % Average expected life (in years) - 10.00 Volatility - % 110 % The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2019 3,417,126 0.25 Warrants granted 1,500,000 0.10 Warrants expired (642,857 ) (0.26 ) Balance, September 30, 2020 4,274,269 $ 0.20 Warrants granted - - Warrants expired (1,739,268 ) 0.25 Balance, September 30, 2021 2,535,001 $ 0.17 Exercisable, September 30, 2021 2,535,001 $ 0.17

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14 – Commitments and Contingencies Legal Contingencies There are no material pending legal proceedings to which we are a party or to which any of our property is subject, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

Impairment Expense

Impairment Expense	12 Months Ended
	Sep. 30, 2021
Impairment Expense
Impairment Expense	Note 15 – Impairment Expense Impairment expense for the years ended September 30, 2021 and 2020 consisted of the following: Schedule of Impairment Expense 2021 2020 September 30, 2021 2020 Inventory impairment $ - $ 37,900 Goodwill impairment - 592,621 Impairment expense $ - $ 630,521 On September 30, 2020, the Company decided to no longer pursue its SabIR technology, which was intended to use MicroNIR devices to test cannabis for THC, CBD and CBG. Accordingly, the Company wrote off its inventory, consisting of five MicroNIR devices, each costing $ 7,580 37,900 Goodwill consisted of the consideration paid in excess of the net fair value of assets acquired and liabilities assumed in the VSSL transaction. On September 30, 2020, the Company performed an impairment analysis and determined the asset to be impaired due to the lack of significant revenues, and the Company’s inability to fund the necessary research and development to develop its assets.

Income Tax

Income Tax	12 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Tax	Note 16 - Income Tax The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the years ended September 30, 2021 and 2020, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At September 30, 2021, the Company had approximately $ 14,200,000 of federal net operating losses. The net operating loss carry forwards, if not utilized, will begin to expire in 2031 . The effective income tax rate for the years ended September 30, 2021 and 2020 consisted of the following: Schedule of Effective Income Tax Rate 2021 2020 September 30, 2021 2020 Federal statutory income tax rate 21 % 21 % State income taxes - % - % Change in valuation allowance (21 )% (21 )% Net effective income tax rate - - The components of the Company’s deferred tax asset are as follows: Schedule of Deferred Tax Asset 2021 2020 September 30, 2021 2020 Deferred tax assets: Net operating loss carry forwards $ 2,983,700 $ 2,971,500 Net deferred tax assets before valuation allowance $ 2,983,700 $ 2,971,500 Less: Valuation allowance (2,983,700 ) (2,971,500 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at September 30, 2021 and 2020, respectively. In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 17 – Subsequent Events Subsequent to September 30, 2021, the Company received the remaining $ 275,000 675,000 Subsequent to September 30, 2021, the company advanced an additional $ 120,000 On October 21, 2021, the Company issued 1,500,000

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Nature of Business	Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory and data analytics company focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015 and has plans to open labs in other states and countries that have legalized the sale of cannabis, beginning with California.
Basis of Accounting	Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.
Principles of Consolidation	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2021: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity (1) Incorporation Relationship Digipath, Inc (2) (2) Nevada Parent Digipath Labs, Inc Nevada Subsidiary TNM News, Inc (6) (6) Nevada Subsidiary GroSciences, Inc (3) (3) Colorado Subsidiary Digipath Labs S.A.S (4) (4) Colombia Subsidiary VSSL Enterprises, Ltd (5) (5) Canada Subsidiary Digipath Labs CA, Inc (7) (7) Nevada Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Commenced operations during the first fiscal quarter of 2019, and had minimal operations until being dissolved on September 30, 2020. (4) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (5) Acquired on March 11, 2020. (6) Dissolved on July 28, 2021, trivial operating expenses during fiscal years September 30 2021 and 2020. (7) Formed during the fourth fiscal quarter of 2021, but has not yet commenced significant operations. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Segment Reporting	Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Accounts Receivable	Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $ 96,285 128,944 The Company had one customer representing 27% 10% 29% 25% 10% 24%
Notes Receivable	Notes Receivable Notes receivable are reported in our consolidated balance sheets at the outstanding principal balance, plus costs incurred to originate the loans, net of any unamortized premiums or discounts on purchased loans. We use the effective interest rate method to recognize finance income, which produces a constant periodic rate of return on the investment. Unearned income, discounts and premiums are amortized to finance income in our consolidated statements of operations using the effective interest rate method. Interest receivable related to the unpaid principal is recorded together with the outstanding balance in our consolidated balance sheets. Upon the prepayment of a note receivable, any prepayment penalties and unamortized loan origination, closing and commitment fees are recorded as part of finance income in our consolidated statements of operations.
Fixed Assets	Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. Our intellectual property is comprised of indefinite-lived brand names acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables.
Advertising Costs	Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $ 28,050 45,120
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2021 and 2020, potential dilutive securities had an anti-dilutive effect and were no
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not.
Uncertain Tax Positions	Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2021: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity (1) Incorporation Relationship Digipath, Inc (2) (2) Nevada Parent Digipath Labs, Inc Nevada Subsidiary TNM News, Inc (6) (6) Nevada Subsidiary GroSciences, Inc (3) (3) Colorado Subsidiary Digipath Labs S.A.S (4) (4) Colombia Subsidiary VSSL Enterprises, Ltd (5) (5) Canada Subsidiary Digipath Labs CA, Inc (7) (7) Nevada Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Commenced operations during the first fiscal quarter of 2019, and had minimal operations until being dissolved on September 30, 2020. (4) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (5) Acquired on March 11, 2020. (6) Dissolved on July 28, 2021, trivial operating expenses during fiscal years September 30 2021 and 2020. (7) Formed during the fourth fiscal quarter of 2021, but has not yet commenced significant operations.
Schedule of Estimated Useful Lives of Property, Plant and Equipment	Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease

Acquisition from Affiliate (Tab

Acquisition from Affiliate (Tables)	12 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identifiable Assets Acquired and Liabilities Assumed	Schedule of Recognized Identifiable Assets Acquired and Liabilities Assumed March 11, 2020 Consideration: Cash $ 200,000 Fair value of 6,500,000 373,750 Liabilities assumed 20,600 Total consideration $ 594,350 Fair value of identifiable assets acquired assumed: Cash $ 143 Accounts receivable 1,586 Total fair value of assets assumed 1,729 Consideration paid in excess of fair value (Impaired Goodwill) (1) $ 592,621 (1) The consideration paid in excess of the net fair value of assets acquired and liabilities assumed was recognized as goodwill and determined to be impaired on September 30, 2020 due to the lack of significant revenues, and our inability to fund the necessary research and development to develop its assets.
Schedule of Business Acquisition Pro Forma Information	The following table sets forth the unaudited pro forma results of the Company as if the acquisition of VSSL was effective on the first day of each of the periods presented. These combined results are not necessarily indicative of the results that may have been achieved had the companies always been combined. Schedule of Business Acquisition Pro Forma Information For the year ended September 30, 2020 (Unaudited) Revenues $ 2,588,803 Net loss $ (2,343,662 ) Basic and diluted net loss per share $ ( 0.04 ) Weighted average number of common shares outstanding - basic and fully diluted 56,350,657

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Sep. 30, 2021
Investments, All Other Investments [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2021 and 2020, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Fair Value Measurements at September 30, 2021 Level 1 Level 2 Level 3 Assets Cash $ 295,957 $ - $ - Liabilities Lease liabilities - - 444,131 Notes payable - 598,941 - Convertible notes payable, net of discounts of $ 98,188 - - 1,307,282 Fair Value Measurements at September 30, 2020 Level 1 Level 2 Level 3 Assets Cash $ 82,749 $ - $ - Liabilities Short term advances - 50,112 - Lease liabilities - - 561,394 Notes payable - 473,224 - Convertible notes payable, net of discounts of $ 8,322 - - 1,241,678 Convertible notes payable, net of discounts of $98,188 and $8,322 - - 1,241,678

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at September 30, 2021 and 2020: Schedule of Fixed Assets 2021 2020 As of September 30, 2021 2020 Software $ 125,903 $ 124,697 Office equipment 71,601 74,777 Furniture and fixtures 29,879 29,879 Lab equipment 1,453,716 1,398,716 Leasehold improvements 494,117 494,117 Lab equipment held under capital leases 99,193 99,193 Fixed assets, gross 2,274,409 2,221,379 Less: accumulated depreciation (1,627,157 ) (1,335,974 ) Total $ 647,252 $ 885,405

Leases (Tables)

Leases (Tables)	12 Months Ended
	Sep. 30, 2021
Leases
Schedule of Components of Lease Expense	The components of lease expense were as follows: Schedule of Components of Lease Expense For the For the Year Ended Year Ended September 30, 2021 September 30, 2020 Operating lease cost $ 118,873 $ 207,772 Finance lease cost: Amortization of assets 19,839 20,224 Interest on lease liabilities 7,310 10,696 Sublease income - (79,285 ) Total net lease cost $ 146,022 $ 159,407
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases was as follows: Schedule of Supplemental Balance Sheet Information September 30, 2021 September 30, 2021 Operating leases: Operating lease assets $ 413,884 $ 505,706 Current portion of operating lease liabilities 93,601 $ 84,731 Noncurrent operating lease liabilities 330,151 423,752 Total operating lease liabilities $ 423,752 $ 508,483 Finance lease: Equipment, at cost $ 99,193 $ 99,193 Accumulated amortization (39,677 ) (19,839 ) Equipment, net $ 59,516 $ 79,354 Current portion of finance lease liabilities $ 20,379 $ 32,532 Noncurrent finance lease liabilities - 20,379 Total finance lease liabilities $ 20,379 $ 52,911 Weighted average remaining lease term: Operating leases 3.92 4.92 Finance leases 0.55 1.55 Weighted average discount rate: Operating leases 5.75 % 5.75 % Finance lease 18.41 % 18.41 %
Schedule of Supplemental Cash Flow and Other Information	Supplemental cash flow and other information related to leases was as follows: Schedule of Supplemental Cash Flow and Other Information For the For the Year Ended Year Ended September 30, 2021 September 30, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows provided by sublet operating leases $ - $ 79,285 Operating cash flows used for operating leases $ 84,731 $ 177,619 Financing cash flows used for finance leases $ 32,532 $ 46,282 Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ - $ 528,616 Total finance lease liabilities $ - $ 99,193
Schedule of Future Minimum Annual Lease Commitments Under Operating Leases	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of September 30, 2021: Schedule of Future Minimum Annual Lease Commitments Under Operating Leases Fiscal Year Ending Minimum Lease September 30, Commitments 2022 $ 115,550 2023 119,468 2024 123,543 2025 116,891 2026 - Total future undiscounted lease payments 475,452 Less interest 51,701 Present value of lease payments 423,752 Less current portion 93,601 Long-term operating lease liabilities $ 330,151
Schedule of Future Minimum Annual Lease Payments Under Finance Lease	Future minimum annual lease payments required under the finance lease and the present value of the net minimum lease payments are as follows at September 30, 2021: Schedule of Future Minimum Annual Lease Payments Under Finance Lease Finance Leases 2022 $ 21,645 2023 - Total minimum lease payments 21,645 Less interest 1,266 Present value of lease liabilities 20,379 Less current portion 20,379 Long-term finance lease liabilities $ -

Short Term Advances (Tables)

Short Term Advances (Tables)	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Short Term Advances	Short term advances consist of the following at September 30, 2021 and 2020, respectively: Schedule of Short Term Advances September 30, 2021 September 30, 2020 On July 20, 2020, we received $ 30,112 8.0 $ $ 30,112 On January 21, 2020, we received $ 20,000 - 20,000 Total short term advances $ - $ 50,112

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at September 30, 2021 and 2020, respectively: Schedule of Notes Payable September 30, 2021 September 30, 2020 On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 6,750,000 12 September 10, 2024 22,419.66 400,000 $ 400,000 $ - On March 23, 2021; April 29, 2021; July 12, 2021; July 22, 2021 and August 23, 2021, we received proceeds of $ 40,000 25,000 7,000 100,000 50,000 8 $ - $ - On June 22, 2020, the Company, borrowed $ 40,114 1.00 June 22, 2025 40,338 $ - $ 40,114 On May 13, 2020, the Company, through its wholly-owned subsidiary Digipath Labs, Inc. (“Labs”), borrowed $ 179,920 1.00 May 13, 2022 182,054 - 179,920 On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five December 26, 2024 198,941 253,190 Total notes payable 598,941 473,224 Less: current maturities (259,425 ) (54,317 ) Notes payable $ 339,516 $ 418,907

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable consist of the following at September 30, 2021 and 2020, respectively: Schedule of Convertible Notes Payable September 30, 2021 September 30, 2020 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 150,000 150,000 On February 10, 2020, the Company completed the sale to an accredited investor of a 9 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 350,000 350,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 On September 30, 2020, the maturity date was extended to August 10, 2022 0.03 90,000 3,000,000 0.03 355,470 December 31, 2022 98,188 355,470 200,000 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 the maturity date was extended to August 10, 2022 0.03 350,000 350,000 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 the maturity date was extended to August 10, 2022 0.03 150,000 150,000 Total convertible notes payable 1,405,470 1,250,000 Less: unamortized debt discounts (98,188 ) (8,322 ) Total convertible debt 1,307,282 1,241,678 Less: current maturities 1,050,000 - Convertible notes payable $ 257,282 $ 1,241,678
Schedule of Interest Expense	The Company recognized interest expense for the years ended September 30, 2021 and 2020, respectively, as follows: Schedule of Interest Expense September 30, 2021 September 30, 2020 Interest on short term loans $ 1,558 $ 61 Interest on capital leases 20,874 10,696 Interest on notes payable 11,302 16,473 Amortization of beneficial conversion features 8,322 33,104 Interest on convertible notes 102,901 87,690 Total interest expense $ 144,957 $ 148,024

Common Stock Options (Tables)

Common Stock Options (Tables)	12 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Summary of Common Stock Options Outstanding	The following is a summary of information about the stock options outstanding at September 30, 2021. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.05 0.13 5,620,000 7.41 $ 0.08 4,370,000 $ 0.08
Schedule of Weighted-Average Assumptions Used for Grants Under Fixed Option Plan	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Weighted-Average Assumptions Used for Grants Under Fixed Option Plan September 30, September 30, 2021 2020 Average risk-free interest rates 0.88 % 0.92 % Average expected life (in years) 5.00 5.00 Volatility 156 % 141 %
Schedule of Activity of Outstanding Common Stock Options	The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2019 6,085,000 0.13 Options issued 3,700,000 0.10 Options repurchased/expired (6,215,000 ) (0.13 ) Balance, September 30, 2020 3,570,000 $ 0.11 Options issued 2,800,000 0.05 Options forfeited (750,000 ) (0.10 ) Balance, September 30, 2021 5,620,000 $ 0.08 Exercisable, September 30, 2021 4,370,000 $ 0.08

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Sep. 30, 2021
Common Stock Warrants
Summary of Common Stock Warrants Outstanding	The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2021 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.10 0.26 2,535,001 5.34 $ 0.17 2,535,001 $ 0.17
Schedule of Fair Value of Warrant with Weighted-Average Assumptions Used for Grants	The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Fair Value of Warrant with Weighted-Average Assumptions Used for Grants September 30, September 30, 2021 2020 Average risk-free interest rates - % 0.46 % Average expected life (in years) - 10.00 Volatility - % 110 %
Schedule of Outstanding Common Stock Warrants Activity	The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2019 3,417,126 0.25 Warrants granted 1,500,000 0.10 Warrants expired (642,857 ) (0.26 ) Balance, September 30, 2020 4,274,269 $ 0.20 Warrants granted - - Warrants expired (1,739,268 ) 0.25 Balance, September 30, 2021 2,535,001 $ 0.17 Exercisable, September 30, 2021 2,535,001 $ 0.17

Impairment Expense (Tables)

Impairment Expense (Tables)	12 Months Ended
	Sep. 30, 2021
Impairment Expense
Schedule of Impairment Expense	Impairment expense for the years ended September 30, 2021 and 2020 consisted of the following: Schedule of Impairment Expense 2021 2020 September 30, 2021 2020 Inventory impairment $ - $ 37,900 Goodwill impairment - 592,621 Impairment expense $ - $ 630,521

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate	The effective income tax rate for the years ended September 30, 2021 and 2020 consisted of the following: Schedule of Effective Income Tax Rate 2021 2020 September 30, 2021 2020 Federal statutory income tax rate 21 % 21 % State income taxes - % - % Change in valuation allowance (21 )% (21 )% Net effective income tax rate - -
Schedule of Deferred Tax Asset	The components of the Company’s deferred tax asset are as follows: Schedule of Deferred Tax Asset 2021 2020 September 30, 2021 2020 Deferred tax assets: Net operating loss carry forwards $ 2,983,700 $ 2,971,500 Net deferred tax assets before valuation allowance $ 2,983,700 $ 2,971,500 Less: Valuation allowance (2,983,700 ) (2,971,500 ) Net deferred tax assets $ - $ -

Schedule of Entities Under Comm

Schedule of Entities Under Common Control and Ownership (Details)	12 Months Ended
	Sep. 30, 2021
Entities Under Common Control And Ownership One [Member]
Name of Entity	Digipath, Inc	[1],[2]
Jurisdiction of Incorporation	Nevada
Relationship	Parent
Entities Under Common Control And Ownership Two [Member]
Name of Entity	Digipath Labs, Inc	[1]
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control And Ownership Three [Member]
Name of Entity	TNM News, Inc	[1],[3]
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control And Ownership Four [Member]
Name of Entity	GroSciences, Inc	[1],[4]
Jurisdiction of Incorporation	Colorado
Relationship	Subsidiary
Entities Under Common Control And Ownership Five [Member]
Name of Entity	Digipath Labs S.A.S	[1],[5]
Jurisdiction of Incorporation	Colombia
Relationship	Subsidiary
Entities Under Common Control And Ownership Six [Member]
Name of Entity	VSSL Enterprises, Ltd	[1],[6]
Jurisdiction of Incorporation	Canada
Relationship	Subsidiary
Entities Under Common Control And Ownership Seven [Member]
Name of Entity	Digipath Labs CA, Inc	[1],[7]
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
[1]	All entities are in the form of a corporation.
[2]	Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company.
[3]	Dissolved on July 28, 2021, trivial operating expenses during fiscal years September 30 2021 and 2020.
[4]	Commenced operations during the first fiscal quarter of 2019, and had minimal operations until being dissolved on September 30, 2020.
[5]	Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations.
[6]	Acquired on March 11, 2020.
[7]	Formed during the fourth fiscal quarter of 2021, but has not yet commenced significant operations.

Schedule of Estimated Useful Li

Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)	12 Months Ended
	Sep. 30, 2021
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment estimated useful lives	Term of lease

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Product Information [Line Items]
Allowance for doubtful accounts	$ 96,285	$ 128,944
Advertising expense	$ 28,050	$ 45,120
Antidilutive Securities Earning per share	0	0
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration Risk, Percentage	27.00%	25.00%
Gross Revenue [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration Risk, Percentage		10.00%
Gross Revenue [Member] | Customer Concentration Risk [Member] | Two Customer [Member]
Product Information [Line Items]
Concentration Risk, Percentage	10.00%
Revenue [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration Risk, Percentage		24.00%
Revenue [Member] | Customer Concentration Risk [Member] | Two Customer [Member]
Product Information [Line Items]
Concentration Risk, Percentage	29.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated (deficit)	$ 17,951,653	$ 17,265,150

Schedule of Recognized Identifi

Schedule of Recognized Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($)		Mar. 11, 2020	Sep. 30, 2021	Sep. 30, 2020
Business Acquisition [Line Items]
Cash				$ 200,000
VSSL Enterprises Ltd [Member]
Business Acquisition [Line Items]
Cash		$ 200,000
Fair value of 6,500,000 shares of common stock		373,750
Liabilities assumed		20,600
Total consideration		594,350
Cash		143
Accounts receivable		1,586
Total fair value of assets assumed		1,729
Consideration paid in excess of fair value (Goodwill)(1)	[1]	$ 592,621
[1]	The consideration paid in excess of the net fair value of assets acquired and liabilities assumed was recognized as goodwill and determined to be impaired on September 30, 2020 due to the lack of significant revenues, and our inability to fund the necessary research and development to develop its assets.

Acquisition from Affiliate - Sc

Acquisition from Affiliate - Schedule of Recognized Identifiable Assets Acquired and Liabilities Assumed (Details) (Parenthetical)	Mar. 11, 2020shares
Business Combination and Asset Acquisition [Abstract]
Number of shares acquired during period, shares	6,500,000

Schedule of Business Acquisitio

Schedule of Business Acquisition Pro Forma Information (Details)	12 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares
Business Combination and Asset Acquisition [Abstract]
Revenues	$ 2,588,803
Net loss	$ (2,343,662)
Basic and diluted net loss per share | $ / shares	$ 0.04
Weighted average number of common shares outstanding - basic and fully diluted | shares	56,350,657

Acquisition from Affiliate (Det

Acquisition from Affiliate (Details Narrative) - USD ($)	Mar. 11, 2020	Mar. 11, 2020	Mar. 09, 2020	Sep. 30, 2021	Sep. 30, 2020
Business Acquisition [Line Items]
Stock issued during period, shares, acquisitions	6,500,000
Cash payment for acquired shares					$ 200,000
Number of shares acquired during period, value					373,750
Goodwill					$ 592,621
Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, acquisitions					6,500,000
Number of shares acquired during period, value					$ 6,500
VSSL Enterprises Ltd [Member]
Business Acquisition [Line Items]
Cash payment for acquired shares		$ 200,000
VSSL Enterprises Ltd [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, acquisitions		6,500,000
Cash payment for acquired shares		$ 200,000
Number of shares acquired during period, value		$ 373,750	$ 373,750
VSSL Enterprises Ltd [Member] | Common Stock [Member] | Mr. Remenda [Member]
Business Acquisition [Line Items]
Equity method ownership percentage			45.00%
VSSL Enterprises Ltd [Member] | Common Stock [Member] | Mr. Henry [Member]
Business Acquisition [Line Items]
Equity method ownership percentage			45.00%
Purchase Agreement [Member] | VSSL Enterprises Ltd [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, acquisitions			6,500,000
Cash payment for acquired shares			$ 200,000
Acquisition occured date			Mar. 11, 2020

Summary of Financial Instrument

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash	$ 295,957	$ 82,749
Lease liabilities
Note payable
Convertible notes payable, net of discounts of $98,188 and $8,322
Short term advances
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash
Lease liabilities
Note payable	598,941	473,224
Convertible notes payable, net of discounts of $98,188 and $8,322
Short term advances		50,112
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash
Lease liabilities	444,131	561,394
Note payable
Convertible notes payable, net of discounts of $98,188 and $8,322	$ 1,307,282	1,241,678
Short term advances

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Financial Instruments at Fair Value on Recurring Basis (Details) (Parenthetical) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Investments, All Other Investments [Abstract]
Convertible notes discounts	$ 98,188	$ 8,322

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2021	Jun. 13, 2019
Defined Benefit Plan Disclosure [Line Items]
Interest Income (Expense), Net	$ 929
Interest Payable	929
Northwest Analytical Labs, Inc. [Member] | Various Dates Between December 28, 2018 and June 13, 2019 [Member]
Defined Benefit Plan Disclosure [Line Items]
Loan received from related party		$ 95,000
Note bearing interest rate		10.00%
C Three Labs Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Loan received from related party	$ 230,000
Note bearing interest rate	8.00%
Debt instrument, maturity date	Aug. 23, 2022

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Software	$ 125,903	$ 124,697
Office equipment	71,601	74,777
Furniture and fixtures	29,879	29,879
Lab equipment	1,453,716	1,398,716
Leasehold improvements	494,117	494,117
Lab equipment held under capital leases	99,193	99,193
Fixed assets, gross	2,274,409	2,221,379
Less: accumulated depreciation	(1,627,157)	(1,335,974)
Total	$ 647,252	$ 885,405

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Line Items]
Loss on dispositions of assets		$ 50,093
Fixed assets		885,405	$ 647,252	$ 885,405
Accumulated depreciation		$ 1,335,974	1,627,157	1,335,974
Depreciation and amortization expense			$ 292,133	$ 323,391
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets	$ 3,176
Chief Executive Officer [Member]
Property, Plant and Equipment [Line Items]
Fixed assets	2,227
Chief Executive Officer [Member] | Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Accumulated depreciation	949
Loss of assets	$ 2,227

Schedule of Components of Lease

Schedule of Components of Lease Expense (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Leases
Operating lease cost	$ 118,873	$ 207,772
Amortization of assets	19,839	20,224
Interest on lease liabilities	7,310	10,696
Sublease income		(79,285)
Total net lease cost	$ 146,022	$ 159,407

Schedule of Supplemental Balanc

Schedule of Supplemental Balance Sheet Information (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Leases
Operating lease assets	$ 413,884	$ 505,706
Current portion of operating lease liabilities	93,601	84,731
Noncurrent operating lease liabilities	330,151	423,752
Total operating lease liabilities	423,752	508,483
Equipment, at cost	99,193	99,193
Accumulated amortization	(39,677)	(19,839)
Equipment, net	59,516	79,354
Current portion of finance lease liabilities	20,379	32,532
Noncurrent finance lease liabilities		20,379
Total finance lease liabilities	$ 20,379	$ 52,911
Weighted average remaining lease term: Operating leases	3 years 11 months 1 day	4 years 11 months 1 day
Weighted average remaining lease term: Finance leases	6 months 18 days	1 year 6 months 18 days
Weighted average discount rate: Operating leases	5.75%	5.75%
Weighted average discount rate: Finance lease	18.41%	18.41%

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow and Other Information (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Leases
Operating cash flows provided by sublet operating leases		$ 79,285
Operating cash flows used for operating leases	84,731	177,619
Financing cash flows used for finance leases	32,532	46,282
Total operating lease liabilities		528,616
Total finance lease liabilities		$ 99,193

Schedule of Future Minimum Annu

Schedule of Future Minimum Annual Lease Commitments Under Operating Leases (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Leases
2022	$ 115,550
2023	119,468
2024	123,543
2025	116,891
2026
Total future undiscounted lease payments	475,452
Less interest	51,701
Present value of lease payments	423,752	$ 508,483
Less current portion	93,601	84,731
Long-term operating lease liabilities	$ 330,151	$ 423,752

Schedule of Future Minimum An_2

Schedule of Future Minimum Annual Lease Payments Under Finance Lease (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Leases
2022	$ 21,645
2023
Total minimum lease payments	21,645
Less interest	1,266
Present value of lease liabilities	20,379	$ 52,911
Less current portion	20,379	32,532
Long-term finance lease liabilities		$ 20,379

Leases (Details Narrative)

Leases (Details Narrative)	12 Months Ended
	Sep. 30, 2021
Leases
Lease expiration date	Aug. 31, 2025

Schedule of Short Term Advances

Schedule of Short Term Advances (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Short-term Debt [Line Items]
Total short term advances		$ 50,112
Convertible Noteholders One [Member]
Short-term Debt [Line Items]
Total short term advances		30,112
Convertible Noteholders Two[Member]
Short-term Debt [Line Items]
Total short term advances		$ 20,000

Schedule of Short Term Advanc_2

Schedule of Short Term Advances (Details) (Parenthetical) - USD ($)	Jul. 20, 2020	Jan. 21, 2020
Convertible Noteholders One [Member]
Short-term Debt [Line Items]
Proceeds from short-term loan	$ 30,112
Short term loan rate of interest	8.00%
Convertible Noteholders Two[Member]
Short-term Debt [Line Items]
Proceeds from short-term loan		$ 20,000

Short Term Advances (Details Na

Short Term Advances (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Short-term Debt [Line Items]
Interest rates on short term loans	$ 1,558	$ 61
Short Term Loan [Member]
Short-term Debt [Line Items]
Interest rates on short term loans	$ 2,356

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
NotesPayableLineItems [Line Items]
Total notes payable	$ 598,941	$ 473,224
Less: current maturities	(259,425)	(54,317)
Notes payable	339,516	418,907
Notes Payable One [Member]
NotesPayableLineItems [Line Items]
Total notes payable	400,000
Notes Payable Two [Member]
NotesPayableLineItems [Line Items]
Total notes payable
Notes Payable Three [Member]
NotesPayableLineItems [Line Items]
Total notes payable		40,114
Notes Payable Four [Member]
NotesPayableLineItems [Line Items]
Total notes payable		179,920
Notes Payable Five [Member]
NotesPayableLineItems [Line Items]
Total notes payable	$ 198,941	$ 253,190

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)

Sep. 10, 2021

Aug. 23, 2021

Jul. 22, 2021

Jul. 12, 2021

Apr. 29, 2021

Mar. 23, 2021

Jan. 12, 2021

Jun. 22, 2020

May 13, 2020

Dec. 26, 2019

Sep. 30, 2021

Sep. 30, 2020

NotesPayableLineItems [Line Items]

Proceeds from notes payable

$ 400,000

$ 220,034

Extinguishment of debt

222,393

Canna Lab Note [Member]

NotesPayableLineItems [Line Items]

Principal amount

$ 6,750,000

Debt instrument interest percentage

12.00%

Debt instrument maturity date

Sep. 10, 2024

Debt instrument periodic payment

$ 22,419.66

Proceeds from notes payable

$ 400,000

Short Term Loans [Member]

NotesPayableLineItems [Line Items]

Debt instrument interest percentage

8.00%

Proceeds from notes payable

$ 50,000

$ 100,000

$ 7,000

$ 25,000

$ 40,000

Company PPP Note [Member] | Cross River Bank [Member]

NotesPayableLineItems [Line Items]

Debt instrument interest percentage

1.00%

Debt instrument maturity date

Jun. 22, 2025

Proceeds from notes payable

$ 40,114

Extinguishment of debt

$ 40,338

Company PPP Note [Member] | WebBank Corp [Member]

NotesPayableLineItems [Line Items]

Extinguishment of debt

$ 182,054

Labs PPP Note [Member] | WebBank Corp [Member] | Digipath Labs, Inc [Member]

NotesPayableLineItems [Line Items]

Debt instrument interest percentage

1.00%

Debt instrument maturity date

May 13, 2022

Proceeds from notes payable

$ 179,920

Note Payable [Member]

NotesPayableLineItems [Line Items]

Debt instrument interest percentage

5.75%

Debt instrument maturity date

Dec. 26, 2024

Debt instrument periodic payment

$ 5,622

Payments for lab equipment

377,124

Proceeds from bank loan

$ 291,931

Debt instrument term description

five

Notes Payable (Details Narrativ

Notes Payable (Details Narrative)	12 Months Ended
	Sep. 30, 2021USD ($)
Note Payable [Member]
NotesPayableLineItems [Line Items]
Interest expense	$ 14,700

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020	Sep. 23, 2019	Feb. 22, 2021
Short-term Debt [Line Items]
Total convertible notes payable	$ 1,405,470	$ 1,250,000
Less: unamortized debt discounts	(98,188)	(8,322)
Total convertible debt	1,307,282	1,241,678
Less: current maturities	1,050,000
Convertible notes payable	257,282	$ 1,241,678
Senior Secured Convertible Note [Member]
Short-term Debt [Line Items]
Debt Instrument, Maturity Date, Description		On September 30, 2020, the maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share.
Debt Instrument, Maturity Date		Aug. 10, 2022	Aug. 10, 2022
Debt Instrument, Convertible, Conversion Price		$ 0.03	$ 0.11	$ 0.03
Debt Instrument, Periodic Payment	$ 355,470
Extended maturity date	Dec. 31, 2022
Convertible Notes Payable One [Member]
Short-term Debt [Line Items]
Total convertible notes payable	$ 50,000	$ 50,000
Convertible Notes Payable Two [Member]
Short-term Debt [Line Items]
Total convertible notes payable	150,000	150,000
Convertible Notes Payable Three [Member]
Short-term Debt [Line Items]
Total convertible notes payable	350,000	350,000
Convertible Notes Payable Four [Member]
Short-term Debt [Line Items]
Total convertible notes payable	355,470	200,000
Convertible Notes Payable Five [Member]
Short-term Debt [Line Items]
Total convertible notes payable	350,000	350,000
Convertible Notes Payable Six [Member]
Short-term Debt [Line Items]
Total convertible notes payable	$ 150,000	$ 150,000

Schedule of Convertible Notes_2

Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)	Sep. 30, 2021	Feb. 22, 2021	Dec. 29, 2020	Dec. 28, 2020	Sep. 30, 2020	Feb. 11, 2020	Feb. 10, 2020	Sep. 23, 2019	Nov. 08, 2018	Nov. 05, 2018	Sep. 30, 2021	Sep. 30, 2020
Short-term Debt [Line Items]
Proceeds from convertible note											$ 267,000	$ 550,000
Amortization of Debt Discount (Premium)											$ 8,322	$ 33,104
Secured Convertible Promissory Note [Member] | Accredited Investors [Member]
Short-term Debt [Line Items]
Debt instrument interest percentage						9.00%
Debt principal amount			$ 10,000	$ 60,000		$ 50,000
Debt instrument, maturity date						Aug. 11, 2022
Conversion price per share			$ 0.03	$ 0.03		$ 0.15
Proceeds from convertible note				$ 10,000
Shares of common stock converted			333,334
Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]
Short-term Debt [Line Items]
Debt instrument interest percentage						9.00%
Debt principal amount			$ 50,000	$ 200,000		$ 150,000
Debt instrument, maturity date						Aug. 11, 2022
Conversion price per share			$ 0.03	$ 0.03		$ 0.15
Proceeds from convertible note				$ 50,000
Shares of common stock converted			1,666,667
9% Secured Convertible Promissory Note [Member] | Accredited Investors [Member]
Short-term Debt [Line Items]
Debt instrument interest percentage							9.00%
Debt principal amount			$ 50,000	$ 400,000			$ 350,000
Debt instrument, maturity date							Aug. 10, 2022
Conversion price per share			$ 0.03	$ 0.03			$ 0.15
Proceeds from convertible note				$ 50,000
Shares of common stock converted			1,666,667
Senior Secured Convertible Note [Member]
Short-term Debt [Line Items]
Debt instrument interest percentage								8.00%
Debt principal amount		$ 90,000						$ 200,000
Debt instrument, maturity date					Aug. 10, 2022			Aug. 10, 2022
Conversion price per share		$ 0.03			$ 0.03			$ 0.11				$ 0.03
Shares of common stock converted		3,000,000
Amortization of Debt Discount (Premium)	$ 98,188
Debt Instrument, Maturity Date, Description					On September 30, 2020, the maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share.
Senior Secured Convertible Note One [Member]
Short-term Debt [Line Items]
Debt instrument interest percentage									8.00%
Debt principal amount									$ 350,000
Debt instrument, maturity date					Aug. 10, 2022				Aug. 10, 2022
Conversion price per share					$ 0.03				$ 0.14			0.03
Debt Instrument, Maturity Date, Description					the maturity date was extended to August 10, 2022
Senior Secured Convertible Note Two [Member]
Short-term Debt [Line Items]
Debt instrument interest percentage										8.00%
Debt principal amount										$ 150,000
Debt instrument, maturity date					Aug. 10, 2022					Aug. 10, 2022
Conversion price per share					$ 0.03					$ 0.14		$ 0.03
Debt Instrument, Maturity Date, Description					the maturity date was extended to August 10, 2022

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Debt Disclosure [Abstract]
Interest on short term loans	$ 1,558	$ 61
Interest on capital leases	20,874	10,696
Interest on notes payable	11,302	16,473
Amortization of beneficial conversion features	8,322	33,104
Interest on convertible notes	102,901	87,690
Total interest expense	$ 144,957	$ 148,024

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Short-term Debt [Line Items]
Convertible notes discounts	$ 98,188	$ 8,322
Amortization of debt discounts	8,322	33,104
Unamortized discounts	$ 98,188	8,322
Maximum Share Amount [Member]
Short-term Debt [Line Items]
Maximum amount owned percentage of issued and outstanding common shares	4.99%
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Convertible notes discounts	$ 98,188	70,964
Amortization of debt discounts	8,322	33,104
Unamortized discounts	98,188
Convertible notes interest expense	$ 102,901	$ 87,690

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	Mar. 11, 2020	Mar. 11, 2020	Mar. 09, 2020	Sep. 30, 2021	Sep. 30, 2020
Class of Stock [Line Items]
Preferred stock, shares authorized				10,000,000	10,000,000
Preferred stock, par value				$ 0.001	$ 0.001
Preferred stock, shares issued				1,325,942	1,325,942
Preferred stock, shares outstanding				1,325,942	1,325,942
Common stock par value				$ 0.001	$ 0.001
Common stock authorized				250,000,000	250,000,000
Common stock, shares issued				71,230,153	58,270,567
Common stock, shares outstanding				71,230,153	58,270,567
Stock issued during period, value, issued for services				$ 256,255	$ 152,550
Number of shares issued					2,000,000
Number of shares acquired during period, shares	6,500,000
Cash payment for acquired shares					$ 200,000
Number of shares acquired during period, value					$ 373,750
Issuance of common stock for compensation, shares				5,392,918	2,702,884
VSSL Enterprises Ltd [Member]
Class of Stock [Line Items]
Cash payment for acquired shares		$ 200,000
Officers [Member]
Class of Stock [Line Items]
Number of shares issued				2,744,585	1,452,884
Board of [Member]
Class of Stock [Line Items]
Number of shares issued				1,898,333
President [Member]
Class of Stock [Line Items]
Number of shares issued				750,000
Third Party Consultant [Member]
Class of Stock [Line Items]
Number of shares issued				1,800,000	200,000
Consultant [Member]
Class of Stock [Line Items]
Stock-based compensation expense				$ 256,255	$ 152,550
Common Stock [Member]
Class of Stock [Line Items]
Sale of Common stock				900,000	706,250
Proceeds from sale of equity				$ 20,250	$ 56,500
Stock issued during period, shares, issued for services				5,392,918	2,702,884
Stock issued during period, value, issued for services				$ 5,393	$ 2,704
Number of shares issued				6,666,668
Debt instrument, face amount				$ 200,000
Number of shares acquired during period, shares					6,500,000
Number of shares acquired during period, value					$ 6,500
Common Stock [Member] | VSSL Enterprises Ltd [Member]
Class of Stock [Line Items]
Number of shares acquired during period, shares		6,500,000
Cash payment for acquired shares		$ 200,000
Number of shares acquired during period, value		$ 373,750	$ 373,750
Common Stock [Member] | Officers [Member]
Class of Stock [Line Items]
Number of shares issued				1,000,000
Common Stock [Member] | Third Party Consultant [Member]
Class of Stock [Line Items]
Number of shares issued					1,250,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized				10,000,000
Preferred stock, par value				$ 0.001
Preferred stock, shares designated				6,000,000
Preferred stock, shares designated remaining				4,000,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued				1,325,942
Preferred stock, shares outstanding				1,325,942
Stock conversion, shares converted					1,325,942
Preferred stock convertible into common stock shares					6,629,710
Percentage of equity beneficial ownership					4.99%
Percentage of distribution on purchase price					1

Summary of Common Stock Options

Summary of Common Stock Options Outstanding (Details)	12 Months Ended
	Sep. 30, 2021$ / sharesshares
Share-based Payment Arrangement [Abstract]
Range of Exercise Price, Minimum	$ 0.05
Range of Exercise Price, Maximum	$ 0.13
Number of Options Outstanding | shares	5,620,000
Weighted Average Remaining Contractual Life	7 years 4 months 28 days
Weighted Average Exercise Price	$ 0.08
Number of Shares Exercisable | shares	4,370,000
Weighted Average Exercise Price Exercisable	$ 0.08

Schedule of Weighted-Average As

Schedule of Weighted-Average Assumptions Used for Grants Under Fixed Option Plan (Details)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Average risk-free interest rates	0.88%	0.92%
Average expected life (in years)	5 years	5 years
Volatility	156.00%	141.00%

Schedule of Activity of Outstan

Schedule of Activity of Outstanding Common Stock Options (Details) - $ / shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Number of Shares Outstanding, Ending balance	3,570,000	6,085,000
Weighted Average Exercise Price, Outstanding, Ending	$ 0.11	$ 0.13
Number of Shares Options issued	2,800,000	3,700,000
Weighted Average Exercise Price, Options issued	$ 0.05	$ 0.10
Number of Shares Options repurchased/expired		(6,215,000)
Weighted Average Exercise Price, Options repurchased/expired		$ (0.13)
Number of Shares Options forfeited	(750,000)
Weighted Average Exercise Price, Options Forfeited	$ (0.10)
Number of Shares Outstanding, Ending balance	5,620,000	3,570,000
Weighted Average Exercise Price, Outstanding, Ending	$ 0.08	$ 0.11
Number of Shares Exercisable	4,370,000
Weighted Average Exercise Price, Exercisable	$ 0.08

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)	Jun. 21, 2016	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding		5,620,000	3,570,000	6,085,000
Number of options granted to purchase shares of common stock		2,800,000	3,700,000
Stock issued during period, value, issued for services		$ 256,255	$ 152,550
Stock option, volatility rate		167.00%	110.00%
Stock option, volatility rate		185.00%	238.00%
Options exercise price per share		$ 0.05	$ 0.10
Stock issued during period, shares, new issues			2,000,000
Weighted average exercise price per share			$ 0.13
Intrinsic value, market price per share		0.042
Intrinsic value weighted-average exercise price per share		$ 0.08
Amortization of Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amortization of stock options		$ 147,630	$ 141,659
Unamortized expenses expected to be expensed		$ 60,628
Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted to purchase shares of common stock			1,500,000
Stock issued during period, shares, new issues		2,744,585	1,452,884
Third Party Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues		1,800,000	200,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, issued for services		$ 5,393	$ 2,704
Stock issued during period, shares, new issues		6,666,668
Weighted average exercise price per share		$ 0	$ 0
Common Stock [Member] | Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues		1,000,000
Common Stock [Member] | Third Party Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues			1,250,000
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted to purchase shares of common stock		2,800,000
Stock issued during period, value, issued for services		$ 142,862	$ 166,953
Stock remaining options vesting period		2 years	2 years
Options exercise price per share		$ 0.05
Equity Option [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted to purchase shares of common stock			3,700,000
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, call option per share		0.0576	$ 0.0683
Options exercise price per share		0.06
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, call option per share		0.0463	$ 0.0403
Options exercise price per share		$ 0.0481
2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding		6,370,000
2012 Stock Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued under stock plan	11,500,000

Summary of Common Stock Warrant

Summary of Common Stock Warrants Outstanding (Details)	12 Months Ended
	Sep. 30, 2021$ / sharesshares
Common Stock Warrants
Range of Exercise Price, Minimum	$ 0.10
Range of Exercise Price, Maximum	$ 0.26
Number of Warrants Outstanding | shares	2,535,001
Weighted Average Remaining Contractual Life	5 years 4 months 2 days
Weighted Average Exercise Price	$ 0.17
Number of Warrants Exercisable | shares	2,535,001
Weighted Average Exercise Price, Exercisable	$ 0.17

Schedule of Fair Value of Warra

Schedule of Fair Value of Warrant with Weighted-Average Assumptions Used for Grants (Details)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Average risk-free interest rates	0.88%	0.92%
Average expected life (in years)	5 years	5 years
Volatility	156.00%	141.00%
Warrant [Member]
Average risk-free interest rates		0.46%
Average expected life (in years)		10 years
Volatility		110.00%

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants Activity (Details) - $ / shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Common Stock Warrants
Number of Shares, Balance ending	4,274,269	3,417,126
Weighted Average Exercise Price, Balance, ending	$ 0.20	$ 0.25
Number of Shares, Warrants granted		1,500,000
Weighted Average Exercise Price, Warrants granted		$ 0.10
Number of Shares, Warrants expired	(1,739,268)	(642,857)
Weighted Average Exercise Price, Warrants expired	$ 0.25	$ (0.26)
Number of Shares, Balance ending	2,535,001	4,274,269
Weighted Average Exercise Price, Balance, ending	$ 0.17	$ 0.20
Number of Shares, Exercisable	2,535,001
Weighted Average Exercise Price, Exercisable	$ 0.17

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative)	Mar. 09, 2020USD ($)$ / sharesshares	Sep. 30, 2021$ / sharesshares	Feb. 21, 2020$ / sharesshares
Number of warrant to purchase of common stock shares | shares		2,535,001
Warrant [Member]
Number of warrant to purchase of common stock shares | shares	1,500,000	1,739,268	642,857
Warrants exercise price per share | $ / shares	$ 0.10	$ 0.25	$ 0.26
Warrants, call option, per share | $ / shares	$ 0.0467
Warrants, call option, value | $	$ 70,012
Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants, measurement input	1.10

Schedule of Impairment Expense

Schedule of Impairment Expense (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Impairment Expense
Inventory impairment		$ 37,900
Goodwill impairment		592,621
Impairment expense		$ 630,521

Impairment Expense (Details Nar

Impairment Expense (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Inventory [Line Items]
Impairment cost		$ 37,900
Five MicroNIR Devices of Each [Member]
Inventory [Line Items]
Impairment cost		$ 7,580

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate (Details)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	21.00%	21.00%
State income taxes
Change in valuation allowance	(21.00%)	(21.00%)
Net effective income tax rate

Schedule of Deferred Tax Asset

Schedule of Deferred Tax Asset (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 2,983,700	$ 2,971,500
Net deferred tax assets before valuation allowance	2,983,700	2,971,500
Less: Valuation allowance	(2,983,700)	(2,971,500)
Net deferred tax assets

Income Tax (Details Narrative)

Income Tax (Details Narrative)	12 Months Ended
	Sep. 30, 2021USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 14,200,000
Operating loss expiration year	2031

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Oct. 21, 2021	Dec. 29, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 10, 2021
Subsequent Event [Line Items]
Number of common stock issued			2,000,000
C Three Labs Inc [Member]
Subsequent Event [Line Items]
Notes Receivable, Related Parties				$ 230,000
Canna Lab Note [Member]
Subsequent Event [Line Items]
Principal amount					$ 6,750,000
Subsequent Event [Member] | A Stone Douglass [Member]
Subsequent Event [Line Items]
Number of common stock issued	1,500,000
Subsequent Event [Member] | C Three Labs Inc [Member]
Subsequent Event [Line Items]
Notes Receivable, Related Parties		$ 120,000
Subsequent Event [Member] | Canna Lab Note [Member]
Subsequent Event [Line Items]
Cash proceeds from debt		275,000
Principal amount		$ 675,000